HOME >> BIOLOGY >> NEWS
Active psoriatic arthritis patients on REMICADE achieve major clinical response in arthritis

SAN DIEGO, CALIF., NOVEMBER 13, 2005 New data, including two-year treatment duration, show a significantly higher proportion of patients with active psoriatic arthritis receiving REMICADE (infliximab) achieved and sustained a high degree of clinical improvement in arthritis, as assessed using the rheumatoid arthritis (RA) definition for "major clinical response," compared with patients receiving placebo. "Major clinical response" is defined as maintenance of a 70 percent improvement in the American College of Rheumatology score (ACR 70) for six continuous months. REMICADE maintenance therapy also resulted in the inhibition of structural damage and significant improvements in functional status and quality of life as maintained over the course of one year. Investigators will present these long-term Phase 2 and 3 study findings this week at the American College of Rheumatology 2005 Annual Scientific Meeting. REMICADE is currently indicated for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis.

"Previous study findings have shown the rapidity and therapeutic intensity of infliximab in treating the joint and skin manifestations associated with active psoriatic arthritis," said Arthur Kavanaugh, MD, Director, Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, and lead study investigator. "These data demonstrate the rapid efficacy of infliximab can be sustained over time, especially as it relates to the arthritic component of this complex disease."

An analysis of two double-blind, placebo-controlled trials, Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) and Induction and Maintenance Psoriatic Arthritis Clinical Trial 2 (IMPACT 2), followed patients for two years (98 weeks) and one year (54 weeks), respectively, and confirmed a significant, high degree of clinical responses in the arthritic component of the disease. Placebo p
'"/>

Contact: Michael Parks
215-325-4010
Centocor, Inc.
16-Nov-2005


Page: 1 2 3 4

Related biology news :

1. Active lifestyle reduces risk of invasive breast cancer
2. Active ingredient in common Chinese herb shown to reduce hypertension
3. Active inbreeding avoidance in wild capuchin monkeys
4. UD awarded $11M for osteoarthritis research and unique mentoring program for women scientists
5. Breakthrough developments in rheumatoid arthritis reported
6. University of Manchester researchers reveal clues to new genes behind rheumatoid arthritis
7. Cartilage discovery offers arthritis hope
8. Rock climbing does not increase risk of osteoarthritis
9. U-M study offers new perspective on nitric oxide signaling in rheumatoid arthritis
10. Turmeric prevents experimental rheumatoid arthritis, bone loss, University of Arizona study shows
11. Can Gleevec help patients with rheumatoid arthritis?

Post Your Comments:
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
(Date:3/20/2015)... Mar. 20, 2015 Research and Markets ... of the "India Sensors Market Forecast and ... The sensor market is projected to grow ... Consumer electronics, automotive, industrial and healthcare sectors ... the country. In addition, adoption of MEMS technology ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
(Date:4/20/2015)...   Meditope Biosciences, Inc ., a biotechnology company ... announced presentation of data demonstrating the use of its ... (ADCs). The data were presented in an abstract at the ... Philadelphia . "We ... the many commercial applications that may be possible for ...
(Date:4/20/2015)... Whitehouse Laboratories is pleased and overly excited ... Food and Drug Administration (FDA) inspection and received no ... GMP compliance inspection, as based upon 21CFR Parts 210 ... 6th and was granted NAI (no action indicated) status. ... Good Manufacturing Practice (GMP) quality system required by the ...
(Date:4/17/2015)... Calif. , April 17, 2015 /PRNewswire/ ... received a SBIR grant from the National ... National Institutes of Health (NIH). The grant ... efforts in the development of breakthrough genomic ... using specially fabricated substrates. Centrillion has been ...
(Date:4/17/2015)... April 17, 2015 CIO Review ( ... its 20 Most Promising Pharma and Life Science Technology ... MediSpend global compliance software platform for life sciences companies. ... by a panel of experts and members of CIO ... “MMIS’s MediSpend Platform has been on our radar for ...
Breaking Biology Technology:Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2
Cached News: